315.25
+1.46%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bajaj Healthcare
Its shares trade on NSE under the ticker BAJAJHCARE.NS. It has been listed since 10 May 2016. In the fiscal year to 31 March 2026, it reported revenue of ₹6.11bn and net income of ₹157.7m. At that date it held total assets of ₹9.23bn and shareholders' equity of ₹5.33bn.
Bajaj Healthcare Ltd. is a pharmaceutical company, which is engages in the development, manufacturing, and supply of amino acids, nutritional supplements, and active pharmaceutical ingredients. The company is headquartered in Thane, Maharashtra. The company went IPO on 2016-05-10. The firm is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. Its segments include Bulk Drugs and Formulations. The company is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. Its APIs include ascorbic acid, CH Base and its derivatives, citicoline sodium, carbamazepine, theobromine, ferrous ascorbate, doxofylline, oxcarbazepine, choline bitartrate and its derivatives, octenidine dihydrochloride, vildagliptin, ticagrelor, diosmin, hesperidin and others. Its FDFs include Cellin 500, Septran DS Tablet, Vitajaj C tables 500mg, Ticajaj 90 tablets, Ecojaj 75mg & 150mg, Deferajaj 400mg & 500mg, Vildajaj 50mg and Vildajaj M 50/500. The company also offers Inositol Nicotinate and Magnesium L-Threonate.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 May 2016
- Employees
- 1,063
- Website
- bajajhealth.com ↗
Leadership
Pay as last reported
- Mr. Sajankumar BajajExecutive Chairman of the Board, Managing Director₹4.8m
- Mr. Amit RajanChief Technology Officer
- Mr. Anil JainJoint Managing Director, Executive Director, since 2004₹4.8m
- Ms. Namrata BajajWhole Time Director, since 2013₹1.0m
- Mr. Pakshal JainWhole Time Director₹1.2m
- Mr. Sandeep ShahNon-Executive Non-Independent Director, since 2025
- Mr. Ram BanarseNon-Executive Independent Director₹125,000
- Mr. Hemant KarnikNon-Executive Independent Director₹218,000
- Mr. Gopalakrishnan KesavanAdditional Non-Executive Independent Director
- Mrs. Kejal ShahNon-Executive Independent Director₹110,000
- Mr. Loukik TipnisNon-Executive Independent Director₹115,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company manufactures a diverse range of active pharmaceutical ingredients.
- It produces specific branded formulations like Cellin 500 and Septran DS.
- Operations are supported by 1,063 full-time employees.
Weaknesses
- The firm relies on a limited set of bulk drug segments.
- Product portfolio focuses heavily on specific amino acids and derivatives.
- Market presence is concentrated in the Indian domestic sector.
Opportunities
- Expansion into nutraceuticals and food industries is possible.
- Growth in global demand for active pharmaceutical ingredients offers potential.
- Development of new formulations can diversify revenue streams.
Threats
- Regulatory changes in the pharmaceutical sector pose compliance risks.
- Intense competition in the bulk drugs and formulations market exists.
- Supply chain disruptions could impact manufacturing capabilities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.